Myeloid derived suppressor cells (MDSCs) are immature myeloid cells characterized by diverse phenotypes and functions. They impair effector functions of immune cells and promote tumor growth, angiogenesis, and tissue damage. In pathologies characterized by chronic inflammation, MDSCs are arrested in their immature state and migrate from the bone marrow to the periphery and to the site of inflammation, where they mediate immunosuppression. When reaching new environments, which exhibit a different array of cytokines, chemokines, and pro-inflammatory mediators, MDSCs sense and adapt to the altered micro-environment by virtue of acquiring different suppressive features/functions that involve changing their cell fate, surface receptors, metabolism and intracellular as well as secreted molecules. This review summarizes some of the latest publications highlighting various layers of MDSC plasticity in relation to different pathologies. We discuss treatments capitalizing on MDSC plasticity aimed at combating MDSCs or manipulating their suppressive activity for improved therapy.
Bibliographical noteFunding Information:
The authors gratefully acknowledge the support of the Society of Research Associates of the Lautenberg Center and the Harold B Abramson Chair in Immunology. This work was supported by the Israel Science Foundation , the joint program between the Israel Science Foundation and the National Natural Science Foundation of China , the Israeli Ministry of Health , the Joint German-Israeli Research Program , the Israel Cancer Research Fund , the NOFAR Program of the Academic Research Office of the Chief Scientist , Ministry of Economy , the Melanoma Research Alliance Funds and the Joseph and Matilda Melnick Funds . The authors thank Hadas Ashkenazi-Preiser, Yaron Meirow, Leonor Daniel, Andrea Simona Safir and Eitan Yefe-Nof for reading and commenting on the manuscript.
© 2018 Elsevier Ltd